Your email has been successfully added to our mailing list.

×
0.0523525513585155 0.0165672630881377 0.000662690523525441 0.0390987408880052 -0.00662690523525514 -0.0198807157057654 -0.0390987408880054 -0.00861497680583183
Stock impact report

Zomedica reports Q4 results [Seeking Alpha]

Zomedica Corp. Common Shares (ZOM) 
US:NYSE Investor Relations: investors.zomedica.com
Company Research Source: Seeking Alpha
When adjusted for non-recurring one-time items, our non-GAAP operating burn was approximately $2.6 million. For the full year 2024, the Company reiterated formal financial guidance, as follows: Zomedica continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of $25.2 million. Recommended For You More Trending News Related Stocks In The News Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
ZOM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ZOM alerts

from News Quantified
Opt-in for
ZOM alerts

from News Quantified